Laser pulses
Colin Kerr
Published: Saturday, September 1, 2018
OD-OS has announced that it has achieved the revocation of the MicroPulse™ Patent (Patent no EP1856774) by Iridex Cooperation in oral proceedings at the European Patent office.
Winfried Teiwes, Managing Director, OD-OS GmbH said: “We fully respect the effort Iridex Cooperation has put into the clinical development how tissue-sparing, shorter laser pulses can be effective for retinal treatments. With Navilas®, we are providing a contact-free, easy-to-use and transparent delivery technique of these laser pulses, which allows standardised treatment protocols. We will work with Navilas® users to make microsecond pulse treatment a non-contact, non-damaging but long-lasting treatment in clinical practice, and a viable addition to often chronical injections.”
www.od-os.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.